Array from Precision Neuroscience.
Source: Precision Neuroscience
Neurotech startup Precision Neuroscience on Thursday announced that a core component of its brain implant system has been approved by the U.S. Food and Drug Administration, a major win for the four-year-old company.
Precision is building a brain-computer interface, or a BCI, which is a system that decodes neural signals and translates them into commands for external technologies. The company’s BCI will initially be used to help patients with severe paralysis restore functions like speech and movement, according to its website.
Only part of Precision’s system was approved by the FDA on Thursday, but it marks the first full regulatory clearance granted to a company developing a wireless BCI, Precision said in a release. Other prominent startups in the space include Elon Musk’s Neuralink, and Synchron, which is backed by Amazon founder Jeff Bezos and Microsoft co-founder Bill Gates.
“This is a foundational moment for Precision,” Dr. Benjamin Rapoport, Precision’s co-founder and chief science officer, said in a statement. Rapoport also helped co-found Musk’s Neuralink in 2017 before departing the following year.
Stephanie Rider of Precision Neuroscience inspects the company’s microelectrode array
Source: Precision Neuroscience
The piece of Precision’s system that the FDA approved is called the Layer 7 Cortical Interface. The microelectrode array is thinner than a human hair and resembles a piece of yellow scotch tape. Each array is made up of 1,024 electrodes.
When it’s placed on the brain, Precision says it can conform to the surface without damaging any tissue.
The FDA authorized Layer 7 to be implanted in patients for up to 30 days, and Precision will be able to market the technology for use in clinical settings. This means surgeons will be able to use the array during procedures to map brain signals, for instance. It’s not Precision’s end goal for the technology, but it will help the company generate revenue in the near term.
Precision has temporarily implanted the Layer 7 in 37 patients so far, and CNBC observed one case at The Mount Sinai Hospital in New York last April. Until this point, the implementations have taken place for short periods, often a matter of minutes or hours, on patients who were already undergoing brain surgery for a medical reason.
Now, thanks to the FDA clearance, the company will be able to collect data for much longer periods of time.
“This regulatory clearance will exponentially increase our access to diverse, high-quality data, which will help us to build BCI systems that work more effectively,” Rapoport said.
